Sneha Phadke is an Oncology physician affiliated with University of Iowa. OpenAlex indexes 54 publications with 316 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Hawkins Dr
C21gh
Iowa City, IA 522421009
Telephone
319-356-2148Registry record last updated 19 May 2016.
Clinical trials
- Accelerated Neuromodulation to Alleviate Cognitive Deficits Due to Cancer Therapy
Sponsor: Sneha Phadke
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
81.8%Aromatase Inhibitor68.7%Anastrozole66%Letrozole24%Exemestane10%Part D<11 patientsKinase inhibitor8.6%Verzenio52%Kisqali25%Ibrance23%Part D<11 patients+ 1 more class in this area
Sensory organs
8.8%Corticosteroid8.8%Dexamethasone100%Part D≥12 patientsNervous system
4%Phenothiazine4%Prochlorperazine Maleate100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Patterns of failure and outcomes in triple-negative compared to estrogen receptor–positive breast cancer.
Journal of Clinical Oncology
2026 - Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers
Breast Cancer Research and Treatment
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Stanley Perlman, MD
University of Iowa
Mohammed Milhem, MBBS
University of Iowa
Lawrence Hunsicker, MD
University of Iowa
Michael Abramoff, MD, PhD
University of Iowa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”